Silver Book Fact

Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients receiving a high-dose lost <15 letters of acuity–compared with 55.6% in the combined low-dose/sham group.  The high-dose group had a 0.6 mean letter gain while the low-dose/sham group had a mean 9.7 letter loss.

Zhang K, Hopkins J, Heier J, Birch D, et al. Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS. 2011; 108(15). http://www.pnas.org/content/early/2011/03/24/1018987108

Reference

Title
Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Publication
PNAS
Publication Date
2011
Authors
Zhang K, Hopkins J, Heier J, Birch D, et al
Volume & Issue
Volume 108, Issue 15
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.